Brought to you by 
Genzyme acquires Ilex for $1bn
Mar 2004
Executive Summary
Oncology therapeutics company Ilex has agreed to be acquired by Genzyme for approximately $1bn in stock. Terms of the deal call for Ilex shareholders to receive Genzyme common stock (0.478 of a share) worth $26 each.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
- Includes Contract
- Full Acquisition
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme acquires Ilex for $1bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice